Literature DB >> 12644219

Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate.

Ray M Merrill1, Charles L Wiggins.   

Abstract

OBJECTIVE: To provide an updated assessment of the influence transurethral resection of the prostate (TURP) has on incidental detection of prostate cancer and to characterize stage, histologic grade, and treatment patterns among these cases.
METHODS: Analyses were based on 17,310 histologically confirmed prostate cancer cases ages 45 years and older recorded in the Utah Cancer Registry between 1980 and 1999 and 6426 TURP procedures recorded in the Utah Hospital Discharge Database from 1992 through 1999. An algorithm was developed for identifying TURP-detected prostate cancer incidence.
RESULTS: Age-specific TURP-detected prostate cancer incidence rates tended to be flat between 1980 and 1990, decline through 1994, and then level off. Much of the decrease corresponds to the prostate-specific antigen (PSA) screening induced peak and subsequent fall in total prostate cancer incidence rates. Leveling off in the TURP-detected rates between 1994 and 1999 corresponds with a leveling off in the total prostate cancer incidence rates. The percentage of prostate cancer detected by TURP significantly increases with age, within each age group, but decreases over calendar years. For ages 45 years and older, the percentage of TURP-detected cases was 39.0% in 1980 to 1984, 33.9% in 1985 to 1989, 12.2% in 1990 to 1994, and 7.4% in 1995 to 1999. TURP-detected cases were significantly less likely to undergo radical prostatectomy or radiation therapy across age groups, despite having lower stage and histologic grade at diagnosis.
CONCLUSION: TURP-detected prostate cancer rates have leveled off in the latter part of the 1990s, explaining about 10% of all detected cases. These cases have relatively good biologic potential and are less likely to pursue aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12644219     DOI: 10.1016/s1078-1439(02)00193-x

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  12 in total

Review 1.  Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia.

Authors:  Jennifer Westwood; Robert Geraghty; Patrick Jones; Bhavan P Rai; Bhaskar K Somani
Journal:  Ther Adv Urol       Date:  2018-08-12

2.  Trends in prostate cancer survival in Spain: results from population-based cancer registries.

Authors:  Rafael Marcos-Gragera; Diego Salmerón; Isabel Izarzugaza; Eva Ardanaz; Bernat-Carles Serdà; Nerea Larrañaga; Erkuden San Román; Carmen Navarro; María-Dolores Chirlaque
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

3.  Incidental finding of prostate cancer in Transurethral Resection of Prostate (TURP) specimens: a retrospective analysis from a Tertiary Care Hospital in Pakistan.

Authors:  Taimoor Khalid Janjua; Muhammad Ali Yousuf; Muhammad Talha Iqbal; Shahbaz Mustafa Memon; Aziz Abdullah; Naveen Faridi; Muhammad Irfan
Journal:  Pan Afr Med J       Date:  2021-05-07

4.  Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.

Authors:  Mattia Luca Piccinelli; Stefano Luzzago; Giulia Marvaso; Ekaterina Laukhtina; Noriyoshi Miura; Victor M Schuettfort; Keiichiro Mori; Abdulmajeed Aydh; Matteo Ferro; Francesco A Mistretta; Nicola Fusco; Giuseppe Petralia; Barbara A Jereczek-Fossa; Shahrokh F Shariat; Pierre I Karakiewicz; Ottavio de Cobelli; Gennaro Musi
Journal:  World J Urol       Date:  2021-10-23       Impact factor: 4.226

5.  Three-dimensional proton magnetic resonance spectroscopy and diffusion-weighted imaging in the differentiation of incidental prostate carcinoma from benign prostate hyperplasia.

Authors:  Xue-Qin Zhang; Xiang-Rong Yu; Zhong-Li Du; Xiao-Fen Miao; Jian Lu; Quan Zhou
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

6.  Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.

Authors:  L Määttänen; M Hakama; T L J Tammela; M Ruutu; M Ala-Opas; H Juusela; P Martikainen; U-H Stenman; A Auvinen
Journal:  Br J Cancer       Date:  2007-01-15       Impact factor: 7.640

7.  Diagnostic role of prostate resection in the elderly patients who experience significant co-morbidity with a high clinical suspicion of prostate cancer.

Authors:  Ho Won Kang; Jin Bak Yang; Whi-An Kwon; Young-Suk Lee; Won Tae Kim; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Isaac Yi Kim; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

8.  Incidence variation of prostate and cervical cancer according to socioeconomic level in the Girona Health Region.

Authors:  Gemma Renart Vicens; Marc Saez Zafra; Judit Moreno-Crespi; Bernat C Serdà Ferrer; Rafael Marcos-Gragera
Journal:  BMC Public Health       Date:  2014-10-17       Impact factor: 3.295

9.  Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.

Authors:  T J Murtola; T L J Tammela; L Määttänen; M Ala-Opas; U H Stenman; A Auvinen
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

10.  Robotic assisted laparoscopic radical prostatectomy following transurethral resection of the prostate: perioperative, oncologic and functional outcomes.

Authors:  Chi-Feng Hung; Cheng-Kuang Yang; Yen-Chuan Ou
Journal:  Prostate Int       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.